Yesterday, the Pulmonary-Allergy Drugs Advisory Committee (PADAC) committee discussed the new drug application (NDA) 21936, for tiotropium bromide inhalation spray, submitted by Boehringer Ingelheim (BI) Pharmaceuticals, Inc. for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and for reducing COPD exacerbations.
August 14, 2014 8:00 a.m. to 4:00 p.m.: Pulmonary-Allergy Drugs Advisory Committee Meeting
Yesterday, the Pulmonary-Allergy Drugs Advisory Committee (PADAC) committee discussed the new drug application (NDA) 21936, for tiotropium bromide inhalation spray, submitted by Boehringer Ingelheim (BI) Pharmaceuticals, Inc. for the long-term, once-daily maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and for reducing COPD exacerbations. The discussion included efficacy data, including the data to support the claim for reduction of COPD exacerbations, but the focus will be on safety findings from the clinical development program and the results of a large safety trial comparing tiotropium bromide inhalation spray and tiotropium bromide inhalation powder.
PADAC voted 10 yes and 3 no, that existing data supports approval of tiotropium bromide inhalation spray. This decision followed a review of the results from eight efficacy clinical trials in which 8,700 patients were treated with tiotropium (in the Respimat device). One of these trials, TIOSPIR (the largest clinical trial conducted in patients with COPD) collected data from more than 17,000 COPD patients from 50 countries.
Respimat is a multi-dose, propellant-free inhaler that uses mechanical energy to generate a slow-moving mist to deliver tiotropium, the same active ingredient as SpirivaHandiHaler (tiotropium bromide inhalation powder). If approved, tiotropium Respimat would provide health providers and their patients with a choice between a mist and dry powder inhaler for the delivery of tiotropium.
Stephen Rennard, Professor, Internal Medicine, Division of Pulmonary, Critical Care, Sleep & Allergy, University of Nebraska Medical Center stated, “As a practicing physician, it’s essential to have multiple treatment choices available when assessing how to help people affected by this devastating disease.”
The FDA is not bound by PADAC’s decision, but takes it into consideration when reviewing the application. If approved, the proposed proprietary name for tiotropium bromide inhalation spray will be Spiriva Respimat.
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComs per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org.
Do you have an upcoming Advisory Committee Meeting?
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us